Relay Therapeutics (RLAY) closed at $17.28 on November 2, 2026, down 5.8% from the previous close, on volume of 2,706,598 shares (30-day average 2,562,124).
Data as of November 2, 2026.
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Wed, 28-Oct 4:12 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Globe Newswire (Tue, 1-Sep 4:46 PM ET)
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Relay Therapeutics' $275 Million Offering Bolsters Pipeline Ambitions—Key Details for Investors
Market Chameleon (Thu, 21-May 4:15 AM ET)
Market Chameleon (Tue, 19-May 3:05 AM ET)
Market Chameleon (Mon, 16-Mar 3:53 AM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of November 2, 2026, RLAY stock price declined to $17.28 with 2,706,598 million shares trading.
RLAY has a beta of 1.96, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.14 to the broad based SPY ETF.
RLAY has a market cap of $3.79 billion. This is considered a Mid Cap stock.
Last quarter Relay Therapeutics reported $350,000 in Revenue and -$.41 earnings per share. This fell short of revenue expectation by $-678,000 and missed earnings estimates by -$.01.
In the last 3 years, RLAY traded as high as $21.27 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
RLAY has outperformed the market in the last year with a price return of +135.4% while the SPY ETF gained +11.7%. However, in the short term, RLAY had mixed performance relative to the market. It has underperformed in the last 3 months, returning -11.2% vs +1.7% return in SPY. But in the last 2 weeks, RLAY shares have fared better than the market returning +6.1% compared to SPY -1.5%.
RLAY support price is $17.66 and resistance is $19.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
